drugset / Trial / NCT00654550

A Study to Assess the Safety, Tolerability and Effect of Nexagon™ Applied to the Eye After PRK Laser Eye Surgery for Nearsightedness

NCT00654550 ↗

Phase 1 Completed 24 enrolled OcuNexus Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

Phase 1 randomized, prospective, double-masked, vehicle-controlled, dose-escalation study to evaluate the safety, tolerability and clinical effect of Nexagon™ in subjects following bilateral PRK for the correction of mild to moderate myopia.

Timeline

Start
2008-04
Primary completion
2008-09
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CODA-001 Unknown — —

Indications